Indoco Remedies Limited reported a standalone net profit of ₹823.20 lakh for the quarter ended June 30, 2026, marking a significant recovery from the net loss of ₹280.70 lakh recorded in Q1FY26. The profitability surge was largely non-operational, driven by an exceptional gain of ₹9,734 lakh recognized from the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. Without this one-time item, the company incurred a pre-tax loss of ₹412 lakh, highlighting that core operational challenges persist despite the bottom-line improvement.

The Board of Directors, at its meeting held on July 28, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, pursuant to Regulation 30 read with Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors M/s. Gokhale & Sathe, Chartered Accountants, who issued an unmodified opinion. Managing Director Aditi Panandikar attributed the revenue growth to resilient domestic formulation sales, noting steady progress in international formulations and API businesses despite a dynamic operating environment.

Standalone Performance

Standalone revenue from operations rose 5.8% year-on-year to ₹4,081.20 lakh, up from ₹3,856.10 lakh in Q1FY26. Domestic sales contributed ₹2,277.50 lakh, while exports accounted for ₹1,803.70 lakh. Total expenses remained high at ₹4,175.60 lakh, including employee benefits of ₹906.50 lakh and other expenses of ₹1,171.20 lakh, keeping operational profitability under pressure.

Consolidated Performance

On a consolidated basis, revenue from operations grew 8.2% year-on-year to ₹4,662.20 lakh, compared to ₹4,308.60 lakh in Q1FY26. Domestic sales reached ₹3,117.70 lakh and international sales stood at ₹1,544.50 lakh. Consolidated EBITDA improved significantly to ₹419 million from ₹103.50 million in the year-ago period, with EBITDA margin expanding to 9.00% from 2.41%. The consolidated loss before exceptional items narrowed to ₹196 million from a loss of ₹367 million in Q1FY26, reflecting improved operating leverage. Consolidated net profit attributable to equity shareholders was ₹649.90 lakh, compared to a loss of ₹357.90 lakh in Q1FY26, with the same exceptional gain of ₹9,734 lakh from the ophthalmic division sale supporting the turnaround. Finance costs stood at ₹282.90 lakh, while depreciation and amortization expenses increased to ₹345.30 lakh.

Key Financial Metrics

*Consolidated figures represent profit attributable to equity shareholders.

What the Numbers Show

The financial results reveal a stark divergence between operational performance and reported profitability. While the company achieved a headline net profit, its core operations continued to generate losses, with standalone profit before exceptional items and tax standing at a deficit of ₹412 lakh. This indicates that the recent profitability is entirely dependent on asset divestment rather than organic business growth. Furthermore, statutory auditors highlighted a material uncertainty regarding the going concern status of FPP Holding LLC, which continues to have a negative net worth of ₹3,822.60 lakh despite earning a net profit of ₹300.89 lakh in the quarter. Management has assessed no impairment provision necessary based on long-term business plans, but the erosion of net worth in this subsidiary remains a key risk factor for investors.

Indoco Remedies Limited will conduct an earnings conference call on July 28, 2026, to discuss the unaudited financial results for the quarter ended June 30, 2026. The meeting is scheduled to begin at 3:30 PM IST, providing investors and analysts with an opportunity to review the company's performance for Q1 FY2026-2027.

The announcement was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was submitted to the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited for information and dissemination.

The conference call will be represented by key members of the company's leadership team. Attendees include Ms. Aditi Panandikar, Managing Director; Mr. Sundeep V. Bambolkar, Joint Managing Director; and Mr. Pramod Ghorpade, Chief Financial Officer.

Participants are encouraged to pre-register using the provided DiamondPass link to avoid waiting queues. The company has provided universal access numbers for domestic participants and international toll-free lines for investors in Hong Kong, Singapore, the USA, and the UK.

For further inquiries regarding the earnings call, stakeholders may contact representatives from Dolat Capital Market Pvt. Ltd., including Rashmi Shetty, Candice Pereira, and Zain Gulam Hussain.

Conference Call Details